Besides, the antitumor activity of USP52 depletion alone was significantly enhanced by ferroptosis induction in vivo, which suggested a sound therapeutic strategy of BLCA patients with high USP52 levels. This evidence concerns the gene PAN2 and bladder transitional cell carcinoma.